Tassone et al. [53] showed high sensitivity of BRCA1-deficient breast cancer cells to vinorelbine and argued that the differences in the mechanism of action between various microtubule interfering drugs have to be considered while interpreting the results of BRCA1 studies. This evidence concerns the gene BRCA1 and breast carcinoma.